Minakata, Daisuke
Uchida, Tomoyuki
Nakano, Aya
Takase, Ken
Tsukada, Nodoka
Kosugi, Hiroshi
Kawata, Eri
Nakane, Takahiko
Takahashi, Hiroyuki
Endo, Tomoyuki
Nishiwaki, Satoshi
Fujiwara, Hideaki
Saito, Akiko M.
Saito, Toshiki I.
Akashi, Koichi
Matsumura, Itaru
Mitani, Kinuko http://orcid.org/0000-0001-9736-9469
Article History
Received: 20 August 2023
Revised: 9 November 2023
Accepted: 17 November 2023
First Online: 3 January 2024
Declarations
:
: IM (ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceutical K.K, NIPPON SHINYAKU CO., LTD., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd, Shionogi & Co., Ltd., TEIJIN PHARMA LIMITED, Boehringer Ingelheim, Sanofi, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., MSD K.K, ASAHI KASEI PHARMA CORPORATION), KM (Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K, TEIJIN PHARMA LIMITED., NIPPON SHINYAKU CO., LTD., TAIHO PHARMACEUTICAL CO., LTD., Takeda Pharmaceutical Company Limited., Otsuka Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and DAIICHI SANKYO COMPANY, LIMITED., Sumitomo Pharma Co., Ltd.) received grants or contracts from any entity. IM (Otsuka Pharmaceutical Co., Ltd), KM (Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Bristol–Myers Squibb) received consulting fee of each company. DM (Janssen Pharmaceutical K.K), HK (Sanofi K.K., Bristol–Meyrs Squibb, Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Japan, Janssen Pharmaceutical K.K., Takeda Pharamaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Japan Blood Products Organization, Daiichi Sankyo Co., Ltd., Glaxo-Smithkline K.K., AbbVie GK, Becton Dickinson Japan), HT (Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Mundi Pharm, Nippon Kayaku Co., Ltd., NIPPON SHINYAKU CO., LTD., Janssen Pharmaceutical K.K, Sanofi, Takeda Pharamaceutical Co., Ltd., Meiji Seika Pharm, Astra Zeneca, Bristol–Meyrs Squibb, Ono Pharmaceutical Co.), IM (Bristol–Myers Squibb, Novartis Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., DAIICHI SANKYO COMPANY, LIMITED., ONO PHARMACEUTICAL CO., LTD., Chugai Pharmaceutical Co., Ltd., AstraZeneca, SymBio Pharmaceuticals, AbbVie GK, Amgen BioPharma K.K.), and KM (NIPPON SHINYAKU CO.,LTD., MSD K.K, Novartis Pharmaceuticals, Pfizer Japan Inc., Bristol–Myers Squibb, Takeda Pharmaceutical Company Limited., Kyowa Kirin Co., Ltd., MOCHIDA PHARMACEUTICAL CO., LTD, AbbVie GK, Alexion Pharmaceuticals, Inc., ONO PHARMACEUTICAL CO., LTD., Otsuka Pharmaceutical Co., Ltd., Sanofi, Janssen Pharmaceutical K.K, SymBio Pharmaceuticals, AstraZeneka, Chugai Pharmaceutical Co., Ltd., CSL Behring, Amgen BioPharma K.K., Fujimoto Pharmaceutical Co., Eisai Co., Ltd., Sumitomo Pharma Co., Ltd., Meiji Seika Pharma, ASAHI KASEI PHARMA CORPORATION, Astellas Pharma Inc.) directly received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from any entity. KM (Kyowa Kirin Co., Ltd.) has received support for attending meetings and/or travel. KM (Novartis Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Bristol–Myers Squibb) participated on a data safety monitoring board or advisory board. TU, AN, KT, NT, EK, TN, TE, SN, HF, AS, TS, and KA have no conflicts of interest to disclose.